Yale Jen

- Evoke Pharma, Inc. has entered into a **definitive agreement to be acquired by QOL Medical, LLC**.  **[1403708_0001193125-25-263544_d48107dex991.htm:0]** 
- QOL Medical will acquire all outstanding shares of Evoke for **$11.00 per share in cash**.  **[1403708_0001193125-25-263544_d48107dex991.htm:0]** 
- This purchase price represents a **139.7% premium** to Evoke’s closing share price on November 3, 2025.  **[1403708_0001193125-25-263544_d48107dex991.htm:0]** 
- The transaction is expected to close by the **end of 2025**  **[1403708_0001193125-25-263544_d48107dex991.htm:0]**  and will result in Evoke ceasing to be a publicly traded company.  **[1403708_0001193125-25-263544_d48107d8k.htm:3]**

Evoke Pharma to Be Acquired by QOL Medical

- QOL Medical, LLC will acquire all outstanding shares of Evoke Pharma, Inc. for **$11.00 per share** in cash.  **[1403708_0da980e5cd6e478bb8dfd7429068b07b_0]** **[1403708_0da980e5cd6e478bb8dfd7429068b07b_1]** 
- This purchase price represents a **139.7% premium** to Evoke’s closing share price on November 3, 2025.  **[1403708_0da980e5cd6e478bb8dfd7429068b07b_0]** 
- The transaction has been unanimously approved by the Boards of Directors of both companies and is expected to close by the **end of 2025**.  **[1403708_0da980e5cd6e478bb8dfd7429068b07b_0]** **[1403708_0da980e5cd6e478bb8dfd7429068b07b_1]** 
- The acquisition highlights the strategic value of Evoke's commercial product, **GIMOTI®** (metoclopramide) nasal spray, which is the first and only FDA-approved nasal spray for acute and recurrent diabetic gastroparesis in adults.  **[1403708_0da980e5cd6e478bb8dfd7429068b07b_0]**

Evoke Pharma (EVOK)